HKG:6915

4 stories mentioning HKG:6915Updated 34d ago

Every FINWIRES story that references HKG:6915, newest first.

Jiangxi Bio Unit Wins China Nod for Veterinary Tetanus Antitoxin

Jiangxi Institute of Biological Products' (HKG:6915) wholly owned subsidiary, Chifeng Bo-en Pharmaceutical, received an approval certificate from Chinese regulators for its veterinary tetanus antitoxin, according to a Friday Hong Kong bourse filing.The product is used to prevent and treat tetanus infections in animals by neutralizing tetanus toxin and providing passive immune protection to animals at risk of infection.

HKG:6915

Asia37d ago

Jiangxi Institute of Biological Products Slumps 34% in Hong Kong Debut

Jiangxi Institute of Biological Products' (HKG:6915) shares opened 33.9% below the offer price in a weak Hong Kong debut on Tuesday morning.The human tetanus antitoxin provider opened at HK$7.40 per share, compared with the offer price of HK$11.20.

HKG:6915

Asia37d ago

Jiangxi Bio Prices Hong Kong IPO at Midpoint, Raises HK$339 Million

Jiangxi Institute of Biological Products (HKG:6915) will receive HK$338.8 million in net proceeds from its initial public offering in Hong Kong after pricing the shares at the midpoint of the indicative range, according to a Monday after-market disclosure.The human tetanus antitoxin provider issued 36.2 million shares at HK$11.20 each, the midpoint of the HK$9.33 to HK$13.06 price range.The Hong Kong public offering portion of the deal was 476.56 times subscribed, with 3.62 million shares allocated, while the international offering was 4.25 times subscribed, with roughly 32.6 million shares allocated.A cornerstone investor was allotted 4.46 million shares, representing 12.3% of the IPO shares.Jiangxi Bio is set to debut on the Hong Kong bourse today, June 30.

HKG:6915

Asia45d ago

Jiangxi Institute of Biological Products Seeks Up to HK$473 Million in Hong Kong IPO

Jiangxi Institute of Biological Products (HKG:6915) launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$473.2 million.The Chinese antiserum company is offering 36.2 million H-shares at an indicative price range of HK$9.33 to HK$13.06 per share, according to a Hong Kong bourse filing.The offering comprises 3.62 million shares for Hong Kong investors and 32.61 million shares for international investors, subject to reallocation and the overallotment option.The offer price is expected to be determined by June 26, with allocation results due by June 29, ahead of the company's planned trading debut on June 30.Net proceeds will be used to expand the company's production and research and development capabilities.The company secured one cornerstone investor who committed to purchasing HK$50 million worth of IPO shares.China International Capital Corp., China Merchants Securities, Futu Securities International, Guosen Securities, CMBC Securities, and Arta Asset Management are serving as the underwriters for the offering.

HKG:6915

Track with the FINWIRES app suite

FolioX

Track HKG:6915 in your portfolio

WheelAI

Analyze HKG:6915 options with the wheel strategy

StockInsider

See market sentiment on HKG:6915